Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Efficient inhibition of RET/papillary thyroid carcinoma oncogenic kinases by 4-amino-5-(4-chloro-phenyl)-7-(t-butyl)pyrazolo[3,4-d]pyrimidine (PP2).

The Journal of clinical endocrinology and metabolism - 1 Apr 2003

Carlomagno Francesca, Vitagliano Donata, Guida Teresa, Basolo Fulvio, Castellone Maria Domenica, Melillo Rosa Marina, Fusco Alfredo, Santoro Massimo

Abstract excerpt

Inappropriate activation of the RET receptor tyrosine kinase causes development of papillary and medullary thyroid cancer. We have previously shown that pyrazolopyrimidine is a potent inhibitor of the RET kinase. Here, we show that 4-amino-5-(4-chloro-phenyl)-7-(t-butyl)pyrazolo[3,4-d]pyrimidine)...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to 3T3 Cells
Share to Carcinoma, Papillary

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Cell Line, Transformed

Share to Gene Rearrangement

Share to Mitogen-Activated Protein Kinases

Share to Proto-Oncogene Proteins c-ret

Share to Pyrimidines

Share to Receptor Protein-Tyrosine Kinases

Source

Identifiers

PMID: 12679489
DOI: 10.1210/jc.2002-021278

Genes

RET

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 1 Sept 2026. Prepared record publication-12679489-2026-09-01.1. Manifest publication-graph-cohort-2026-09-01.1.

Source receipt: PubMed via Helena Literature Corpus, retrieved 1 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Efficient inhibition of RET/papillary thyroid carcinoma oncogenic kinases by 4-amino-5-(4-chloro-phenyl)-7-(t-butyl)pyrazolo[3,4-d]pyrimidine (PP2).PMID 12679489Read ↗

Identification of RET kinase inhibitors as potential new treatment for sporadic and inherited thyroid cancer.Semantic proximity Read ↗

Inhibition of transforming activity of the ret/ptc1 oncoprotein by a 2-indolinone derivative.Semantic proximity Read ↗

Identification of a novel 5-amino-3-(5-cyclopropylisoxazol-3-yl)-1-isopropyl-1H-pyrazole-4-carboxamide as a specific RET kinase inhibitor.Semantic proximity Read ↗

BAY 43-9006 inhibition of oncogenic RET mutants.Semantic proximity Read ↗

RET kinase inhibitors: a review of recent patents (2012–2015)Semantic proximity Read ↗

Development of RET Kinase Inhibitors for Targeted Cancer TherapySemantic proximity Read ↗

Identification of Novel Small Molecule Inhibitors of Oncogenic RET Kinase.Semantic proximity Read ↗

Inhibitors of Raf kinase activity block growth of thyroid cancer cells with RET/PTC or BRAF mutations in vitro and in vivo.Semantic proximity Read ↗

Discovery of 4-methyl-N-(4-((4-methylpiperazin- 1-yl)methyl)-3-(trifluoromethyl)phenyl)-3-((6-(pyridin-3-yl)-1H-pyrazolo[3,4-d]pyrimidin-4-yl)-oxy)benzamide as a potent inhibitor of RET and its gatekeeper mutant.Semantic proximity Read ↗

Discovery of 4-chloro-3-(5-(pyridin-3-yl)-1,2,4-oxadiazole-3-yl)benzamides as novel RET kinase inhibitors.Semantic proximity Read ↗

PDGFRα Regulates Follicular Cell Differentiation Driving Treatment Resistance and Disease Recurrence in Papillary Thyroid Cancer.Semantic proximity Read ↗

Structural optimization and structure-activity relationship studies of N-phenyl-7,8-dihydro-6H-pyrimido[5,4-b][1,4]oxazin-4-amine derivatives as a new class of inhibitors of RET and its drug resistance mutants.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.